This next post and the one folloing were both deleted , but
This next post and the one folloing were both deleted , but I think brought up some important concerns:
****
I'm very concerned because the media is stressing the need for vaccinations as if it's a "cure-all!"
People are rightly confused and frustrated...
And most aren't avidly watching the world as Covid sweeps through different populations and creates terrifying new variants that will make mincemeat of our unprepared and oblivious population.
And meanwhile the FDA will not approve or grant an EUA to the only drug that stands a chance to help AND should already be in the process of mass production as I write this.
Even if approved, due to the FDA's CRIMINAL delay, there's no where near enough to go around! So the next question will be who gets and who doesn't.
And do YOU think it's going to just ANYBODY. Be prepared for a serious revolt from a maddened populace.
You want to see chaos - the FDA is helping to prepare the stage for a massive upheaval of civil discontent!
Sorrowfully written - so sad and the pile of dead will grow exponentially and civil unrest will not be a picnic either.
FDA reconsider your position and the best interests of our country while you can!!! There still might be time - but not much. We need approval ASAP and production of Leronlimab ramped up immediately!!!
IMO
****
Oh, well - the above was off topic
And here was the follow up post
****
et the former post sink in...
This is big trouble for everyone. I remember Mussolini and his lady "hanging around" after the Italians surrendered. Not a pretty picture...and I don't want to see it here involving my fellow citizens.
With adequate preparation and planning we can avoid this situation. But we have to contend with those that cannot see reality through their haze of greed.
We desperately need Leronlimab approved and in massive production NOW
NOW
NOW
NOW!!!!!!!
NOT JUST MY OPINION BUT A REPLAY OF HISTORY THAT WE DON'T WANT!!
****
Okay not wanting to waste your time, but as an avid supporter of Leronlimab (and a very old person) I don't have a lot of time to put up with the foolishness encountered on Ihub. What I mentioned in the last two posts above is a real concern.
If and when Leronlimab is approved are YOU and ME going to be able to get some from the very limited supply? Or is it going to be handed out to only the select insiders? This could be a very contentious affair and when people you care about are dying while others are flaunting their good fortune>>> I can't picture a good outcome.
Thank you for your tolerance. Learning53/PAfiddler
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
An Unexpected Collaboration to Watch Sometimes partnerships come out of left field, like this one between Cognizant and the European Bank for Reconstruction and Development (EBRD). These two are teaming up to inject some serious tech smarts into the Bank's operations over the next five years. What's interesting here is the role AI and automation play in their grand...
Continue Reading
AI Meets SAP in Customer Experience Revolution Alright, let's cut through the tech chatter. Parloa’s Agent Management Platform has hitched its wagon to SAP as a spiffy Solution Extension. This isn't just tech fluff—it’s a big step for scratching that CX itch companies have. By merging Parloa's AI magic with SAP's existing mojo, businesses get a toolset to enhance...
Continue Reading
The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...
Continue Reading
Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...
Continue Reading
Revolutionizing Compliance with Avery Actions A brand spanking new player has stepped onto the compliance stage, and it's swinging a pretty big AI bat. SurgeONE.ai unveiled Avery Actions, an industry-first agentic AI platform that's aiming to wrangle all your compliance, cybersecurity, and data governance operations under one interoperable umbrella. It's a bold move, and...
Continue Reading
Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...
Continue Reading
The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...
Continue Reading
Why a Trade Fair Needs Lion Dances October 2026 marks a time when talking about a trade fair means diving headfirst into a whirlpool of global exchange and cultural tango we don’t often see in the West. Yeah, I'm looking at you, Canton Fair—a long-runner over in China that's managed to haul in the globe to not just showcase wares, but bring people together in a clash...
Continue Reading
Docusign Brings Its A-Game with SAP Partnership Waking up to find Docusign (NASDAQ:DOCU) teaming up with SAP is like getting a surprise deal at the Saturday market—unexpected but welcome. These two giants in their respective fields are joining forces to plant Docusign’s Intelligent Agreement Management (IAM) directly into SAP Sales Cloud and SAP SuccessFactors. If...
Continue Reading
A New Chapter in Natural Gas Who would have thought? EQT Corporation, that sturdy old veteran in the natural gas game, finally made its move and snatched up Range Resources, sprinting right out of left field. This merger isn't just about two companies shaking hands; it's about rewriting the entire narrative of America's natural gas landscape. With this acquisition, EQT's...
Continue Reading
Top 5 Most Recently Viewed Articles
Recognition at Snowflake Summit dbt Labs, recognized as a leader in the AI-ready structured data domain, has accomplished a significant milestone by being named the 2025 Snowflake Monetization Data Cloud Product Partner of the Year. This accolade highlights their relentless commitment toward delivering exceptional outcomes for their mutual clients. Empowering Customers in...
Continue Reading
The Rise of Stablecoins: A New Financial Landscape As economic instability looms around the world, experts are observing a remarkable surge in stablecoins—digital currencies designed to maintain a stable value. This trend is particularly notable in countries experiencing high inflation where conventional fiat currencies are failing. The growth in stablecoins is...
Continue Reading
Upstart Holdings Under Legal Fire: What's at Stake? Alright, folks, picture this: Upstart Holdings, ticker UPST for those trading on the NASDAQ, is taking a hot seat. Why? They've been slapped with a class-action lawsuit for securities violations. It's no walk in the park when a firm gets accused of making false moves in the stock market game. A Closer Look at the...
Continue Reading
The Evolution of Agriculture Through Drones As the global agriculture drones market reaches new heights, experts predict a remarkable expansion driven by innovation and technology. This rapidly growing sector is set to rise substantially, suggesting a bright future for farmers embracing aerial technology. With increasing demands for efficiency in crop management, the...
Continue Reading
AmpliTech Group Announces Q3 2025 Earnings Release AmpliTech Group, Inc. (NASDAQ: AMPG), known for its innovative approach in the field of signal processing, is set to release its Q3 2025 earnings report before the market opens on an anticipated date. This release is crucial for shareholders and potential investors looking to understand the company's financial health and...
Continue Reading